Genmab Says Phase 3 Trial of Petosemtamab Combination Meets Both Primary Endpoints; Shares Rise

10:37 AM EDT, 10/28/2026 (MT Newswires) -- Genmab (GMAB) said Wednesday that a phase 3 trial of petosemtamab plus pembrolizumab met both primary endpoints. The study evaluated the combination in patients with first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma. The combination was compared with pembrolizumab alone, the company said. The first interim analysis assessed by an independent data monitoring committee showed the trial met both primary endpoints, showing a statistically significant improvement in overall survival and objective response rate, regardless of human papillomavirus, or HPV, status, the company said. The combination reduced the risk of death by 50% compared with pembrolizumab alone, the company added. Following the positive results, the company plans to engage with global regulatory authorities, it said. Shares of Genmab rose past 20% in the session. Price: 53.88, Change: +9.21, Percent Change: +20.61